

February 13, 2025
J-Pharma Co., Ltd.

Georgetown University Receives Use Patent in Japan for LAT1 Inhibitor to Treat Inflammatory Diseases of the Central Nervous System including Multiple Sclerosis
LAT1 inhibitor developments initiate new therapeutic possibilities

J-Pharma Co. Ltd. (Headquarters: Yokohama, Kanagawa, Japan; President & CEO: Masuhiro Yoshitake) announced today that Georgetown University has been granted a patent in Japan for the use of LAT1 inhibitors in the treatment of inflammatory diseases of the central nervous system (Application No.: JP 2021-518005).

This patent is based on the results of a joint research project between the two parties, and J-Pharma has entered into an agreement with Georgetown University granting an exclusive worldwide license to this patent.

With the acquisition of this patent, J-Pharma will expand the possibility of realizing innovative technology in the field of central nervous system disease treatment and will promote further product development and business expansion. This achievement is the result of our ongoing collaboration with Georgetown University, and J-Pharma remains committed to the challenge of drug discovery to meet the expectations of our shareholders, patients and families who have high expectations for our target drug, and the medical community. To realize this goal, J-Pharma will steadily advance development plans while considering the appropriate balance of risk and return and will actively pursue funding and partnerships.

[Reference]

News about the License Agreement with Georgetown University (June 3, 2024)

<https://www.j-pharma.com/en/archives/2176>

Inquiries:

J-Pharma Co., Ltd.

Administration Department

Public Relations

<https://www.j-pharma.com/en/contact>